MD6 Archives - 2021 CMSC Annual Meeting

October 25, 2021

Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar

Background: Satralizumab reduced relapse risk vs placebo in neuromyelitis optica spectrum disorder (NMOSD) patients and had a favourable...

Read More →

Poster-Quality of Life and Outcomes

October 25, 2021

Multiple Sclerosis, Cognition and the Ability to Participate in Social Roles and Activities: Disease Impact Beyond Physical Disability

Background: Multiple Sclerosis is central demyelinating disease that often results in visible motor and coordination or ambulation impact...

Read More →

Poster-Quality of Life and Outcomes

October 25, 2021

Improving Communication about Multiple Sclerosis: The MS-Support Decision Aid

Background: Good communication between patients and their health care provider (HCP) is essential for shared decision making (SDM). We...

Read More →

Poster-Imaging

October 25, 2021

Could Cerebral Autoregulatory Collapse Explain Cognitive Impairment in MS?

Background: Cognitive impairment occurs in almost 70% of multiple sclerosis (MS) patients. The pathophysiology of this impairment is...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More →

Poster-Epidemiology and Genetics

October 25, 2021

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohns Disease

Background: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P1 and S1P5, is approved in the US...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Eculizumab in Nmosd and MG Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions

Background: Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More →

2021 CMSC Annual Meeting

Tag: MD6

Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar

Multiple Sclerosis, Cognition and the Ability to Participate in Social Roles and Activities: Disease Impact Beyond Physical Disability

Improving Communication about Multiple Sclerosis: The MS-Support Decision Aid

Could Cerebral Autoregulatory Collapse Explain Cognitive Impairment in MS?

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohns Disease

Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder

Safety of Eculizumab in Nmosd and MG Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

MAILING ADDRESS

CONTACT US

FOLLOW US